We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook
Read MoreHide Full Article
Clovis Oncology Inc shares declined more than 12% on Oct 8. A day earlier The Goldman Sachs Group, Inc. (GS - Free Report) reportedly lowered its price target from $13 to $3 and maintained its “Sell” rating for Clovis. An analyst at Goldman Sachs cited rising competition that will hurt Clovis’ top line as the reason for a lower price target.
The rating company stated that longer-term consensus estimates for Clovis were based on growth in sales of Rubraca, a PARP inhibitor, following potential label expansions in prostate cancer and first-line maintenance setting for ovarian cancer in combination with Bristol-Myers’ (BMY - Free Report) PD-1 inhibitor, Opdivo.
Please note that Rubraca is the sole marketed drug in Clovis’ portfolio. This PARP inhibitor is approved as a maintenance treatment for recurrent ovarian cancer, irrespective of BRCA-mutation, in second-line setting. The drug is also approved as third or later-line treatment for BRCA-mutant ovarian cancer.
Llast month, AstraZeneca and Merck presented encouraging data from two phase III studies — PROfound and PAOLA-1 — evaluating their PARP inhibitor, Lynparza, in patients with prostate cancer and first-line maintenance setting for ovarian cancer, respectively. Competitive data from these studies on Lynparza creates a challenging setup for Rubraca which has led Goldman Sachs to reduce sales estimates for Rubraca by a fourth. The rating company also stated that high cash burn and debt burden to support label expansion of Rubraca will also put pressure on Clovis’ margin.
Clovis’ stock has declined 82.4% so far this year compared with the industry's decrease of 8.5%.
Although sales of Rubraca registered strong year-over-year growth in the first half of 2019, competition is intensifying in the PARP inhibitor segment. Apart from Lynparza, two other FDA-approved PARP inhibitors — Pfizer’s (PFE - Free Report) Talzenna and Glaxo’s Zejula — are also available in the market. Glaxo has also successfully completed a late-stage study evaluating Zejula as first-line maintenance therapy for ovarian cancer.
Other PARP inhibitors are marketed by large-cap pharmaceuticals, which have strong cash resources to support expansion of their drugs. Successful development of Rubraca in additional indications is necessary for it to sustain momentum in a competitive field.
Clovis is diversifying its pipeline to ward off some competition. In September, the company signed a global licensing and collaboration agreement with privately-held, Germany-based biotech 3B Pharmaceuticals. The deal will grant Clovis rights to fibroblast activation protein alpha (FAP)-targeted radiopharmaceutical program.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook
Clovis Oncology Inc shares declined more than 12% on Oct 8. A day earlier The Goldman Sachs Group, Inc. (GS - Free Report) reportedly lowered its price target from $13 to $3 and maintained its “Sell” rating for Clovis. An analyst at Goldman Sachs cited rising competition that will hurt Clovis’ top line as the reason for a lower price target.
The rating company stated that longer-term consensus estimates for Clovis were based on growth in sales of Rubraca, a PARP inhibitor, following potential label expansions in prostate cancer and first-line maintenance setting for ovarian cancer in combination with Bristol-Myers’ (BMY - Free Report) PD-1 inhibitor, Opdivo.
Please note that Rubraca is the sole marketed drug in Clovis’ portfolio. This PARP inhibitor is approved as a maintenance treatment for recurrent ovarian cancer, irrespective of BRCA-mutation, in second-line setting. The drug is also approved as third or later-line treatment for BRCA-mutant ovarian cancer.
Llast month, AstraZeneca and Merck presented encouraging data from two phase III studies — PROfound and PAOLA-1 — evaluating their PARP inhibitor, Lynparza, in patients with prostate cancer and first-line maintenance setting for ovarian cancer, respectively. Competitive data from these studies on Lynparza creates a challenging setup for Rubraca which has led Goldman Sachs to reduce sales estimates for Rubraca by a fourth. The rating company also stated that high cash burn and debt burden to support label expansion of Rubraca will also put pressure on Clovis’ margin.
Clovis’ stock has declined 82.4% so far this year compared with the industry's decrease of 8.5%.
Although sales of Rubraca registered strong year-over-year growth in the first half of 2019, competition is intensifying in the PARP inhibitor segment. Apart from Lynparza, two other FDA-approved PARP inhibitors — Pfizer’s (PFE - Free Report) Talzenna and Glaxo’s Zejula — are also available in the market. Glaxo has also successfully completed a late-stage study evaluating Zejula as first-line maintenance therapy for ovarian cancer.
Other PARP inhibitors are marketed by large-cap pharmaceuticals, which have strong cash resources to support expansion of their drugs. Successful development of Rubraca in additional indications is necessary for it to sustain momentum in a competitive field.
Clovis is diversifying its pipeline to ward off some competition. In September, the company signed a global licensing and collaboration agreement with privately-held, Germany-based biotech 3B Pharmaceuticals. The deal will grant Clovis rights to fibroblast activation protein alpha (FAP)-targeted radiopharmaceutical program.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. price | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>